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Whole genome sequence analysis of the
TALLYHO/Jng mouse
James Denvir, Goran Boskovicˆ, Jun Fan, Donald A. Primerano, Jacaline K. Parkman and Jung Han Kim*
Abstract
Background: The TALLYHO/Jng (TH) mouse is a polygenic model for obesity and type 2 diabetes first described in the
literature in 2001. The origin of the TH strain is an outbred colony of the Theiler Original strain and mice derived from
this source were selectively bred for male hyperglycemia establishing an inbred strain at The Jackson Laboratory. TH
mice manifest many of the disease phenotypes observed in human obesity and type 2 diabetes.
Results: We sequenced the whole genome of TH mice maintained at Marshall University to a depth of approximately
64.8X coverage using data from three next generation sequencing runs. Genome-wide, we found approximately 4.31
million homozygous single nucleotide polymorphisms (SNPs) and 1.10 million homozygous small insertions and
deletions (indels) of which 98,899 SNPs and 163,720 indels were unique to the TH strain compared to 28 previously
sequenced inbred mouse strains. In order to identify potentially clinically-relevant genes, we intersected our list of SNP
and indel variants with human orthologous genes in which variants were associated in GWAS studies with obesity,
diabetes, and metabolic syndrome, and with genes previously shown to confer a monogenic obesity phenotype in
humans, and found several candidate variants that could be functionally tested using TH mice. Further, we filtered our
list of variants to those occurring in an obesity quantitative trait locus, tabw2, identified in TH mice and found a
missense polymorphism in the Cidec gene and characterized this variant’s effect on protein function.
Conclusions: We generated a complete catalog of variants in TH mice using the data from whole genome sequencing.
Our findings will facilitate the identification of causal variants that underlie metabolic diseases in TH mice and will enable
identification of candidate susceptibility genes for complex human obesity and type 2 diabetes.
Keywords: Whole genome sequencing, Obesity, Type 2 diabetes, Mouse model, TALLYHO, Quantitative Trait Loci
Background
The high prevalence of obesity and type 2 diabetes is a
serious public health issue that is associated with devas-
tating health consequences such as cardiovascular
diseases [1, 2]. The World Health Organization estimated
that more than 10 % of the world’s adult population (200
million men and 300 million women) was obese (body mass
index ≥30 kg/m2) in 2008 (http://www.who.int/mediacentre/
factsheets/fs311/en/) and that, in 2012, 347 million people
had diabetes, 90 % of whom had type 2 diabetes (http://
www.who.int/mediacentre/factsheet/fs312/en/). Genetic pre-
disposition is recognized as a major risk factor for
the development of obesity and type 2 diabetes; esti-
mates of the heritability range from 50 % to 60 % for
both diseases [3]. Therefore, identification of under-
lying susceptibility genes would define potential tar-
gets and pathways for intervention and treatment of
obesity and type 2 diabetes.
The genetics of human obesity and type 2 diabetes is
complex [4, 5]. It involves multiple susceptibility genes
and their interactions with environmental factors [6].
Animal models that share both physiologic and genetic
similarity with humans are used in obesity and type 2
diabetes research to minimize the confounding effects of
heritability, genetic heterogeneity and environment that
determine these diseases in humans [7, 8].
The TALLYHO/Jng (TH) mouse is a polygenic inbred
model for human obesity and type 2 diabetes [9]. TH
mice manifest many of the disease phenotypes observed
in human obesity and type 2 diabetes including hyper-
leptinemia, hyperinsulinemia, insulin resistance, glucose
intolerance, hyperlipidemia, and hyperglycemia [10].
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These mice also exhibit increased islet insulin secretion
in response to glucose and β-cell mass [11]. The genetic
basis for obesity and type 2 diabetes in TH mice has
been studied using outcross experiments with normal
strains which has led to the identification of multiple
quantitative trait loci (QTLs) linked to adiposity and
hyperglycemia [10].
In addition to genetic analysis, the TH mouse has been
used in the development of therapeutic agents for obes-
ity and type 2 diabetes [12, 13] and has also served as a
model system for many diabetes and obesity related
abnormalities, including decreased exercise capacity
[14], impaired wound healing [15–17], periodontitis [18],
tissue susceptibility to hypoxia [19, 20], bone loss [21,
22], circadian disruption [23], and vasculature abnormal-
ities [24–26].
In this study, we sequenced the whole genome of the
TH mouse using next-generation sequencing with the
goal of identifying genome-wide sets of single nucleotide
polymorphisms (SNPs) and small insertions and dele-
tions (indels), a subset of which are present exclusively
in the TH mouse (private variants). A complete cata-
logue of TH genomic variants (public and private) will
aid the identification of causative variants and genes
underlying the diseases observed in TH mice, which will
maximize the relevancy of this model for human obesity
and type 2 diabetes. Knowing the distribution of variants
across the genome of the TH mouse vs. other classic
and wild-derived inbred strains [27] may identify natur-
ally occurring gene variant sets that can represent model
genes for the complex human obesity and type 2
diabetes. As a proof of principle, we integrated our
genome variant data with genetic mapping data and
identified a variant in cell death-inducing DFFA-like
effector c (Cidec) whose effect on protein function
we characterized.
Methods
Description and origin of the TH mouse strain
The TH mouse is originally derived from an outbred
colony of the Theiler Original strain in which two male
mice spontaneously became polyuric, glucosuric, hyper-
insulinemic, and hyperglycemic (Harrow, United
Kingdom) [28]. In 1994, male diabetic progeny and ap-
parently normal female mice were imported into The
Jackson Laboratory (TJL) (Bar Harbor, ME, USA) and an
inbred strain was then established by selecting for male
hyperglycemia by Dr. Jürgen Naggert’s research group at
TJL. In 2001, a sub-colony was initiated in our labora-
tory with breeding pairs from Dr. Naggert’s research
colony [10] and used in this study. After arrival at our
laboratory, we interbred siblings for 18 generations
followed by one generation backcrossing and an
additional 14 generations of sibling interbreeding. Since
the generation prior to arrival at our laboratory re-
mains unknown, we refer to the generation used for
whole genome sequencing in this study as F? +
F18N1F14. All animal studies were carried out with
the approval of Marshall University Animal Care and
Use Committee.
DNA sequencing, read alignment, and bioinformatics
High quality genomic DNA was extracted from the liver
of a male TH mouse from our colony using a Qiagen
(Valencia, CA) Genomic-tip 100/G kit. Genomic DNA
(1 μg) was sheared using a Covaris (Woburn, MA) S2 in-
strument to ~350 bp and used to construct a sequencing
library using an Illumina (San Diego, CA) DNA Sample
Preparation kit according to the manufacturer’s recom-
mended protocol. The library was quantified using
ThermoFisher (Waltham, MA) Qubit fluorimetry and
sized on an Agilent (Santa Clara, CA) Bioanalyzer DNA
chip. The resulting whole genome library (8 pmole) was
amplified on a flow cell using an Illumina cBot cluster
station and then sequenced on an Illumina HiSeq 1000
in the Marshall University Genomics Core Facility.
Three sequencing runs (one 2x50 bp paired-end and two
2x100 bp paired-end) were performed in order to obtain
adequate depth of coverage.
Sequencing reads were aligned to the C57BL/6J (B6)
reference genome (GRCm38, mm10) using Bowtie2
v2.1.0 [29]. Our variant calling pipeline was based on
that developed by Wong et al. [30] to call variants in the
FVB/NJ mouse strain. Briefly, duplicate reads were
removed with SAMtools v0.1.18 [31] using the “samtools
rmdup” command. To improve quality of the variant
calling, local realignment around insertions and dele-
tions was performed using GATK v3.2.2 [32] by first
running the “RealignerTargetCreator” command and
then the “IndelRealigner” command. SNPs and indels
were called by generating a pileup using the “samtools
pileup” command with options uEDS, and piping the
results to the “bcftools view” command with options “-p
0.99 –vbcgN”. Variants were filtered using the VCFtools
package [33] version 0.1.12. In order to maintain maximal
consistency with the Mouse Genome Project (MGP) [34],
we used the same options as in Wong et al. [30].
We identified variants in the TH strain that did not
occur in any of the 28 mouse strains published in the
MGP (Additional file 1: Table S1), which we term “pri-
vate” variants, following Keane et al. [34]. To do this, we
generated a list of all genomic locations of TH variants
in the form of a bed file, and then performed variant
calling on the bam files for the 28 MGP mouse strains at
those locations, using SAMTools’ “–l” option along with
the same parameters as were used to call TH variants.
TH SNPs qualified as private if no MGP strain had the
same SNP at the same location, where at least 21 of the
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28 strains had a call quality at least 20 and read depth at
least 5 at that location. TH indels qualified as private if
no MGP strain had a variant at the same genomic loca-
tion, with the same criteria for call quality and read
depth being applied.
We then added functional consequence annotation, in-
cluding “Sorting Intolerant From Tolerant” (SIFT) [35]
prediction of protein function changes of coding vari-
ants, using a local installation of Ensembl Variant Effect
Predictor (VEP) version 77 [36]. Output from VEP
includes classification of each variant using a set of one
or more Sequence Ontology (SO) terms [37]. Variants
are classified multiple times if they lie within a region
intersecting multiple known transcripts. We tabulated
the number of variants according to their collection of
SO terms, collecting into a single “Multiple Classifica-
tion Sets” group all variants that had multiple, distinct
sets of SO terms due to their presence in multiple
transcripts. Since this latter group is large, and may
include potentially interesting variants, we identified a
set of ten SO terms we call “potentially pathogenic”:
frameshift_variant, inframe_deletion, inframe_insertion,
missense_variant, stop_gained, stop_lost, initiator_codon_-
variant, splice_region_variant, splice_acceptor_variant, and
splice_donor_variant. We tabulated the number of
variants in the “multiple classification sets” that clas-
sified with each of these SO terms for one or more
transcripts. The same classification was performed on
the private variants. For missense variants, we add-
itionally used Protein Variation Effect Analyzer v 1.1
(PROVEAN) [38] to provide further prediction of the
functional effects of protein changes.
In order to uniquely associate a representative SO
term with each variant, we chose a single representative
SO term for each distinct set of SO terms identified for
a given variant in a given transcript, as shown in
Additional file 2: Table S2 and Additional file 3: Table
S3. For example, 32 SNPs were classified with the two
SO terms “intron_variant” and “splice_region_variant”:
for these SNPs we chose “splice_region_variant” as the
representative term. Using this process, variants
occurring in multiple transcripts that had multiple,
distinct sets of SO terms associated with them, re-
sulted in having multiple representative SO terms. For
such variants, we chose the “most pathogenic” representa-
tive SO term, ordering them in the following priority:
“stop_gained”, “stop_lost”, “frameshift_variant”, “missense_-
variant”, “inframe_insertion”, “inframe_deletion”, “splice_ac-
ceptor_variant”, “splice_donor_variant”, “splice_region_vari
ant”, “initiator_codon_variant”, “synonymous_variant”,
“5_prime_UTR_variant”, “3_prime_UTR_variant”, “ma-
ture_miRNA_variant”, “upstream_gene_variant”, “down-
stream_gene_variant”, “intron_variant”, “non_coding_tran
script_variant”, “intergenic_variant”.
In order to compare our variant sets to known associ-
ations between genetic variants and human traits for
which TH is a model, we first retrieved the Genome
Wide Association Study (GWAS) catalog [39] from the
European Bioinformatics Institute (EBI) (https://www.e-
bi.ac.uk/gwas/), and filtered the catalog by the column
“DISEASE/TRAIT” for each of the terms “obesity”, “dia-
betes”, and “metabolic”. For each filtered catalog, we
extracted all human Entrez GeneIDs listed in the
columns MAPPED GENE(S), UPSTREAM_GENE_ID,
and DOWNSTREAM_GENE_ID. Using the Ensembl
interface to BioMart [40], we converted these Entrez
GeneIDs to Ensembl human gene IDs. Additionally, we
retrieved a list of genes from Pigeyre et al. [41] in which
mutations have been previously shown to cause a mono-
genic obesity phenotype in humans, and found Ensembl
IDs for these genes using the same tool. For all these
human Ensembl gene IDs, we found Ensembl mouse
gene IDs of orthologous genes, again using the Ensembl
interface to Biomart. We then filtered our variant sets
(SNPs, indels, private SNPs, and private indels) to iden-
tify potentially pathogenic variants associated with each
of these orthologous gene sets.
Aligned reads were uploaded to the Sequence Read
Archive (SRA) at the National Center for Biotechnology
Information (NCBI) and can be accessed via accession
number SRP067703.
Cell culture, plasmids, transfections, and microscopy
COS-1 cells (ATCC, Manassas, VA) were grown in
Dulbecco’s modified Eagle’s medium with L-glutamine,
4.5 g/L glucose and sodium pyruvate (Mediatech,
Manassas, VA) supplemented with 10 % (v/v) bovine
serum (Sigma, St. Louis, MO) and 100 units/ml penicillin
and 100 mg/ml streptomycin (Mediatech, Manassas, VA).
The murine Cidec cDNA was procured from
GenScript (Piscataway, NJ). A Green Fluorescent Protein
fusion, pAcGFP1-CIDEC was created by cloning the
Cidec cDNA with 5′ HindIII and 3′ BamHI sites up-
stream and in-frame with the AcGFP1 sequence in
pAcGFP1-N1 (Clontech, Mountain View, CA). The en-
tire Cidec coding region was included except for the stop
codon [42]. Site-directed mutagenesis was used to intro-
duce the missense polymorphism R46S (GeneScript,
Piscataway, NJ). Plasmids, pAcGFP1-CIDEC (R46) and
pAcGFP1-CIDEC (S46), were transfected into COS-1
cells cultured on 4-well chamber slides (1 x 105 cells per
chamber) (Thermo Scientific, Waltham, MA) using
Lipofectamine LTX&PLUS (Life Technologies, Grand
Island, NY) following the manufacturer’s instruction
[43]. COS cells do not express endogenous CIDEC [44].
After transfection, the cells were cultured for 48 h with
and without 400 μM BSA-complexed oleic acid (Sigma)
[45]. Cells were then washed with PBS, fixed by 4 %
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paraformaldehyde for 30 min, and permeabilized in
0.05 % (w/v) saponin (Sigma) in PBS for 20 min. Lipids
were stained with 1 μg/ml Nile red (Sigma) which parti-
tions with neutral lipids; cells were washed with PBS
(6x). Nuclei were labeled by placing coverslips onto
slides with Prolong® Gold Antifade Mountant with DAPI
(Life Technologies). Coverslips were dried and cells
viewed on a Leica SP5 confocal microscope located in
the Marshall University Imaging Center. Each experi-
ment was performed in quadruplicate samples. Associ-
ation of full length Cidec with lipid droplets in COS-1
cells was assessed using ImageJ software by performing a
co-localization analysis of GFP florescence with Nile red
labeled lipid droplets in each z-section of a transfected
cell [43]; these results were then averaged to calculate
the overall co-localization in a given cell (the ratio of
Nile red signal specifically associated with GFP signal to
GFP signal). The data were from 12 cell clusters in each
condition from two independent experiments. Quantita-
tive data were presented as means ± SEM. Two-tailed
Student’s t-tests were performed on data. Differences of
P < 0.05 were considered significant.
Results
Identification of SNPs and indels
The whole genome of the TH mouse was sequenced to
an average depth of ~64.8X coverage using data from
three Illumina paired-end read sequencing runs. The
sequencing reads were mapped to the B6 mouse refer-
ence genome (GRCm38/mm10). Using a SAMTools-
based pipeline [31], we identified 4,370,213 SNPs
(4,310,548 of which were homozygous) and 1,213,617
indels (1,065,090 of which were homozygous) genome-
wide, relative to the reference strain C57BL/6 (B6). The
positional distribution of variants on each chromosome
is shown in Fig. 1. To assess the reliability of our data,
PCR amplification and Sanger sequencing were applied
to 14 homozygous SNPs to determine whether they
agreed with next generation sequencing results (Add-
itional file 4: Table S4). We found that all 14 SNPs were
consistent with the Illumina sequencing data.
We observed a small percentage of heterozygous SNPs
and indels in the TH genome (1.37 % and 12.24 %, re-
spectively). Possible explanations for the apparent pres-
ence of heterozygosity include errors in variant calling,
true residual heterozygosity, and recent heterozygous
mutations not yet fixed to homozygosity [46]. We did
not consider heterozygous SNPs and indels in our subse-
quent analyses.
Functional consequences of SNPs and indels
We assigned putative functional consequences to the set
of homozygous variants (SNPs and indels) in TH using
Variant Effect Predictor (VEP) [36], which classified the
variants using terms from the Sequence Ontology (SO)
[37] (Additional file 2: Table S2 and Additional file 3:
Table S3). Variants which intersected multiple tran-
scripts, and for which the set of SO terms associated
with the variant differs among those transcripts, were
categorized as “multiple classification sets”. For each of
ten SO terms we designated “potentially pathogenic”
(see Methods), we counted the number of variants in
the “multiple classification sets” category that classified
under that SO term in one or more transcripts.
For each distinct collection of SO terms identified
for a variant, we chose a representative term (as
shown in Additional file 2: Table S2 and Additional
file 3: Table S3). For variants with multiple classifica-
tion sets this potentially resulted in multiple represen-
tative SO terms: for these variants with multiple
classifications we categorized the variant as the “most
pathogenic” according to the prioritization defined in
the methods. This resulted in a unique SO term for
each variant: the distributions of these SO terms
among SNPs and indels are shown in Figs. 2 and 3,
respectively. The majority of SNPs were either inter-
genic (50.2 %) or intronic (29.2 %). The next two
largest SNP groups were those which were located
5 kb upstream (8.95 %) or downstream (7.38 %) from
a coding gene. A small number of SNPs (less than
1 % of the total) were located within the protein cod-
ing regions of gene bodies. SNP variants resulted in
21,039 synonymous codon changes, 10,829 non-
synonymous codon changes, 63 conversions of coding
codons to stop codons and 34 conversions of stop
codons to coding codons.
There were 10,829 SNPs causing non-synonymous
changes to one or more protein-coding transcripts in
4,351 genes. We evaluated the effect of the amino acid
substitutions resulting from the SNPs using SIFT [35,
47] (as implemented by VEP) and PROVEAN [38].
These algorithms classify the changes as either deleteri-
ous (SIFT score < 0.05, or PROVEAN score < -2.5) or
tolerated/neutral (SIFT/PROVEAN). SIFT classified
14.8 % of the non-synonymous substitutions (1601 sub-
stitutions) in 1,148 genes as deleterious. PROVEAN clas-
sified 9.6 % (1041 substitutions) in 772 genes as
deleterious. 4.8 % of the missense variants (512 substitu-
tions) in 444 genes were classified as deleterious by both
algorithms.
As expected, the vast majority (99.83 %) of TH indels
fell into noncoding groups (either intergenic, intronic,
5 kb upstream or downstream of coding genes, 5′ or 3′
UTR, or non-coding transcript variants). The total
in-frame and frameshift indels were 362 and 203, re-
spectively (Fig. 3). Proportions of SNPs and indels in
each functional class are similar to those found in the
FVB/NJ genome [30] (Table 1).
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Comparison to the human genome-wide association
study catalog and to known mendelian obesity genes
In order to interpret our data in the context of human
disease, we collected human gene IDs in which variants
were associated with obesity, diabetes, or metabolic syn-
drome, from the EBI GWAS catalog version 1.0.1 [39].
These gene IDs were mapped to orthologous mouse
Ensembl gene IDs using the Ensembl interface to
BioMart [40], generating sets of orthologous mouse
genes. We additionally collected a list of known Mendel-
ian obesity genes in humans from Pigeyre et al. [41], and
generated a set of mouse orthologous genes as afore-
mentioned. We then filtered the potentially pathogenic
TH variants against these gene sets to provide lists of
potentially pathogenic variants for each of these diseases.
We found 26 genes with potentially pathogenic variants
in the GWAS obesity gene set, 85 in the GWAS diabetes
gene set, and 246 in the GWAS metabolic gene set.
Additionally, we found 13 genes with potentially patho-
genic variants orthologous to genes known to cause
monogenic syndromic obesity, four orthologous to genes
known to cause monogenic non-syndromic obesity,
and three orthologous to genes known to cause
monogenic non-syndromic lipodystrophy (Table 2,
Additional file 5: Table S5).
TH private SNPs and indels
We identified variants that were present in the TH strain
and absent from 28 MGP strains by passing the bam
files for each strain through our variant-calling pipeline
at each location where we identified a TH variant. A TH
SNP was identified as “private” if it was not called as the
same SNP in any of the other 28 strains, and a TH indel
was identified as “private” is no variant was identified at
the same location in any of the other 28 strains.
Additionally, the designation of “private” required a call
quality at least 20 and read depth at least 5 in at least 21
of the 28 strains. In this analysis, we identified a total of
98,899 private SNPs and 163,720 private indels, which
represented 2.29 % and 15.4 % of the total SNPs and
indels, respectively.
We classified private variants by SO term using VEP
as described in the analysis for all variants above. Of the
98,899 private SNPs, 358 were missense substitutions,
four resulted in the gain of a stop codon, and one in the
loss of a stop codon (Additional file 6: Table S6 and
Additional file 7: Table S7, Figs. 4 and 5). Among the
163,720 private indels, 42 were frameshift indels and 26
were in-frame indels (Additional file 6: Table S6 and
Additional file 7: Table S7, Figs. 4 and 5). For these
private SNPs and indels, along with those associated by
Fig. 1 Distribution of detected variants on the TH genome. Total number of variants (black), number of SNPs (blue), and number of indels (red)
per megabase as a function of genomic position. These were calculated by sliding a one-megabase window across each chromosome in steps of
one kilobase and totaling the number of variants in the window
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VEP with splice regions and initiator codons, we
counted the number of such variants occurring in each
gene. There were 961 private SNPs meeting one or more
of these criteria in 372 genes (Additional file 8: Table S8)
and 576 private indels meeting one or more of these
criteria in 215 genes (Additional file 9: Table S9). For
the private SNPs, we found that 91 of the 372 genes
had one or more private SNPs determined by SIFT to
be deleterious missense variants, 69 had one or more
private SNPs determined by PROVEAN to be dele-
terious, with 44 genes having SNPs determined to be
deleterious by both algorithms.
In the analysis linking our variant lists with human
GWAS studies and human Mendelian obesity genes
described above, we determined the number of variants
in orthologous genes which were private to the TH
mouse (Table 2).
Characterization of the tabw2 obesity QTL interval on
chromosome 6
Tabw2 (TALLYHO associated body weight 2) is a major
obesity QTL identified in TH mice, and confirmed by a
congenic strain on the B6 background [48]. Using sub-
congenic analysis we have determined that the effect of
tabw2 on obesity could be attributed to two adjacent
loci, tabw2a and tabw2b [49]. There are 411 and 73 pro-
tein coding genes cataloged in the Ensembl mouse anno-
tation database in the tabw2a (6:80,217,217-125,356,646
in coordinates relative to GRCm38) and tabw2b
(6:133,853,029-144,639,629) intervals, respectively. A
total of 123,971 SNPs and 28,622 indels were found in
the tabw2a and tabw2b intervals, of which 68,233 SNPs
and 15,747 indels were in protein-coding genes (Table 3).
Among those, only 5 SNPs (in 5 genes) in the tabw2a
interval and 2 SNPs (in 2 genes) in the tabw2b interval
Fig. 2 Classification of SNPs by Sequence Ontology term. The large pie chart shows the characterization of all TALLYHO/Jng SNPs relative to the
C57BL/6 reference genome; the smaller chart shows the distribution of the subset of these we term “potentially pathogenic”, as described in
the methods
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Fig. 3 Classification of Indels by Sequence Ontology term. The large pie chart shows the characterization of all TALLYHO /Jng indels relative to the
C57BL/6 reference genome; the smaller chart shows the distribution of the subset of these we term “potentially pathogenic”, as described in the methods
Table 1 Comparison of distribution of variants in TALLYHO/Jng to that in FVB/NJ
FVB/NJ TALLYHO/Jng
Percentage of all SNPs Percentage of all indels Percentage of all SNPs Percentage of all indels
5 kb upstream or downstream 7.731 % 9.895 % 7.496 % 8.167 %
5′ or 3′ UTR 0.434 % 0.433 % 0.291 % 0.298 %
Intronic 19.360 % 19.880 % 18.896 % 19.057 %
Synonymous coding 0.307 % 0.204 %
Non-synonymous coding 0.176 % 0.103 %
Essential splice site 0.000 % 0.000 % 0.000 % 0.001 %
Stop gain 0.002 % 0.000 % 0.000 % 0.000 %
Stop lost 0.000 % 0.000 % 0.000 % 0.000 %
In-frame codon insertion or deletion 0.016 % 0.011 %
Frameshift 0.014 % 0.005 %
Two or more consequences 15.436 % 15.710 % 20.401 % 21.467 %
Within, or 5Kb upstream or downstream
from, non-coding gene or mature microRNA
6.240 % 6.280 % 2.362 % 2.403 %
Intergenic 50.314 % 47.772 % 50.246 % 48.591 %
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were classified as deleterious by both SIFT and PRO-
VEAN (shown in bold in Table 4). We then conducted a
literature review of the biological function of the 29
genes in the tabw2 interval with SNPs classified as dele-
terious by either algorithm, searching for potential link
to obesity (Table 4). From this search, the Cidec gene,
containing a SNP identified as deleterious by both SIFT
and PROVEAN, drew our attention. CIDEC is a lipid
droplet protein that is involved in the regulation of
cellular lipid droplet size and lipid storage during lipid
metabolism in adipocytes [50]. A loss of function muta-
tion in CIDEC causes a familial partial lipodystrophy
[43]. Further, weight loss via a low calorie diet was
correlated with a reduced gene expression of CIDEC in
adipose tissue in humans [51].
There was one nucleotide substitution in the Cidec
coding sequence, 136 C > A. The substitution of 136
Table 2 Variants in genes linked to traits of interest by GWAS or
in Mendelian obesity genes
Source Total
genes
SNPs Indels Private
SNPs
Private
Indels
GWAS obesity 26 62 7 3 0
GWAS diabetes 85 208 27 7 2
GWAS metabolic
syndrome
246 594 85 27 3
Monogenic
syndromic obesity
13 45 2 0 0
Monogenic
non-syndromic
obesity
4 3 1 0 0
Monogenic
non-syndromic
lipodystrophy
3 4 0 0 0
Fig. 4 Classification of Private SNPs by Sequence Ontology term. The large pie chart shows the characterization of all TALLYHO/Jng SNPs relative
to the C57BL/6 reference genome that are not present in 28 previously sequenced strains; the smaller chart shows the distribution of the subset
of these we term “potentially pathogenic”, as described in the methods
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C > A resulted in an amino acid difference of R46S
(Arginine 46 Serine) between B6 and TH strains (R46
in B6; S46 in TH). To examine the function of the
Cidec R46S polymorphism, we created murine plas-
mids AcGFP1-CIDEC (R46) and AcGFP1-CIDEC
(S46) and transiently transfected them into COS-1
cells. COS-1 cells have been used as models for mon-
itoring CIDEC function in prior studies because they
lack endogenous Cidec activity [42–44]. It was appar-
ent that AcGFP1-CIDEC was localized to distinct
lipid droplets stained with Nile red (Fig. 6). When we
considered Nile red lipid staining specifically associ-
ated with GFP fluorescence (co-localization), COS-1
cells transfected with the S46 variant exhibited an
increase in lipid accumulation compared to cells
transfected with the wild type R46 variant in the
media both with and without oleic acid (Fig. 6). We
Fig. 5 Classification of Private Indels by Sequence Ontology term. The large pie chart shows the characterization of all TALLYHO/Jng indels
relative to the C57BL/6 reference genome that are not present in 28 previously sequenced strains; the smaller chart shows the distribution of the
subset of these we term “potentially pathogenic”, as described in the methods
Table 3 Numbers of variants in the tabw2 locus
Region
Tabw2a Tabw2b
Total SNPs 81,303 42,668
In protein coding genes 43,878 24,355
Potentially pathogenic 247 107
SIFT deleterious 22 8
PROVEAN deleterious 9 9
Total indels 20,814 7,808
In protein coding genes 11,302 4,445
Potentially pathogenic 38 11
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Table 4 SNPs in the tabw2 locus identified as deleterious by SIFT or PROVEAN
Gene Location on Chr 6 (bp) Codon
Ref/TH
A.A.
Ref/TH
Exon SIFT score PROVEAN score Function Ref
Gcfc2 81923813 tCt/tTt S/F 1/18 0.05 -2.5 Unknown [59]
81933786 cCa/cAa P/Q 5/18 0.02 1.05
81941369 Cgg/Tgg R/W 7/17 0 -5.41
Ccdc142 83107557 cCt/cTt P/L 7/11 0.15 -2.97 Unknown
Htra2 83053837 Ggg/Cgg G/R 1/7 0 N/A Serine protease [60]
83054296 cCt/cTt P/L 1/7 0 -2.04
Mogs 83118580 Cgc/Tgc R/C 4/4 0.03 0.94 Endoplasmic reticulum glucosidase [61]
Rtkn 831151299 Ccc/Gcc P/A 12/13 0.14 -4.41 Rho effector protein [62]
83151312 gCc/gTc A/V 11/12 0.03 -1.1
1700003E16Rik 83162665 aCc/aTc T/I 4/4 0.01 -1.12 Unknown
Tet3 83404686 Ctt/Ttt L/F 3/3 0.01 -1.65 5-methylcytosine oxidase [63]
Aak1 86965533 aAt/aGt N/S 14/21 0.09 -2.66 Endocytosis [64]
Gfpt1 87053776 aCa/aTa T/I 4/5 0 -0.48 Hexosamine biosynthesis [65]
D6Ertd527e 87111649 ACc/CTc T/L 2/2 N/A -4.67 Unknown
Chchd6 89467434 Cgt/Tgt R/C 5/8 0.03 -3.51 Mitochondrial protein [66]
Zfyve20 92199851 cGg/cAg R/Q 7/12 0.02 -1.32 Regulate the intracellular
route of internalized receptors
[67]
Lmod3 97252294 aGt/aAt S/N 1/3 0.02 -0.55 Actin thin filament length regulation [68]
Ttll3 113409684 Ggg/Agg G/R 2/2 0.04 -1.33 Glycylases [69]
Cidec 113433131 Cgt/Agt R/S 3/6 0 -5.85 Lipid storage and lipid droplet formation [70]
Irak2 113647785 Ctg/Gtg L/V 2/12 0 -2.4 Toll-like receptor signaling [71]
Rpl28-ps4 117213939 cAa/cGa Q/R 1/1 0 -0.09 Unknown
Ret 118179286 aCc/aTc T/I 5/20 0 -3.05 Proto-oncogene [72]
Cacna1c 118602267 aCt/aAt T/N 42/47 0.43 -2.93 L-type Ca2+ channel [73]
Cecr5 120510398 Cgt/Tgt R/C 8/8 0.04 -1.85 Unknown
A2m 121639361 atG/atA M/I 3/36 0.02 -0.6 Protease [74]
121661523 aCg/aAg T/K 21/36 0 -5.88
8430419L09Rik 135209106 tCg/tTg S/L 2/2 N/A -6.0 Unknown
135209130 aTg/aCg M/T 2/2 N/A -6.0
135209172 cAg/cGg Q/R 2/2 N/A -4.0
135209250 cGg/cAg R/Q 2/2 N/A -4.0
135209265 gCc/gTc A/V 2/2 N/A -4.0
Atf7ip 136561386 tCg/tTg S/L 3/4 0.01 -0.72 Transcriptional cofactor [75]
136561422 aGt/aCt S/T 3/4 0.05 -0.12
BC049715 136840037 Act/Cct T/P 1/1 0.11 -3.22 Unknown
136840106 Aga/Gga R/G 1/1 0.37 -2.86
136840191 aTg/aCg M/T 1/1 0.01 -4.56
Art4 136857180 Ccc/Acc P/T 1/3 0.02 -1.15 ADP-ribosyltransferase [76]
Mgp 136872651 aAa/aGa K/R 4/4 0.02 -0.33 Calcification inhibitor [77]
Ptpro 137368083 aCg/aTg T/M 2/27 0.03 -1.93 Tumor suppressor [78]
Igbp1b 138658041 aCg/aTg T/M 1/1 0.05 -1.27 Regulation of phosphatase
activity in neuronal cells
[79]
Pik3c2g 139967890 Agt/Tgt S/C 16/16 0.01 -2.86 Long-term Akt2 activation [80]
Chr chromosome, A.A. amino acid, Ref reference, TH TALLYHO
SNPs predicted to be deleterious by both SIFT and PROVEAN are shown in bold
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speculate that the S46 variant may be hypermorphic
in that it enhances the function of CIDEC in promot-
ing lipid accumulation in lipid droplets.
Discussion
Landscape of the TALLYHO genome
We found a total of 5,375,638 variants (SNPs and indels)
in the TH genome, compared to the reference B6 gen-
ome (GRCm38). As expected, the large majority of vari-
ants occurred in non-protein coding regions of the
genome. The number of SNPs was broadly consistent
with that reported by Keane et al. and Wong et al. for 13
laboratory strains [30, 34], and substantially fewer than
the four wild-derived strains (PWK/PhJ, CAST/EiJ,
WSB/EiJ, and SPRET/EiJ) sequenced in the Keane et al.
study [34]. We found 3.5 % to 33.6 % more indels when
compared to those 13 laboratory strains, and again con-
siderably fewer than the four wild-derived strains. The
proportion of private SNPs we observed was higher than
10 of the laboratory strains from Keane et al. [34], with
Fig. 6 Representative images of lipid droplets in COS-1 cells transfected with (a and b) AcGFP1-CIDEC (R46) and (c and d) AcGFP1-CIDEC (S46).
a and c present cells cultured in media without oleic acid (OA) and b and d present cells cultured in media with OA. Images of nuclei labeled
with DAPI, neutral lipid labeled with Nile red and location of AcGFP1 were merged. e Quantification of lipid specifically associated with GFP in
cells. Using ImageJ software, the ratio of Nile red/GFP signal was calculated from 34 lipid droplet clusters each for R46 and S46 without OA and
47 lipid droplet clusters for R46 and 46 lipid droplet clusters for S46 with OA. Data are presented as means ± SEM. *P < 0.05
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the two exceptions being the two strains NOD/ShiLtJ
and NZO/HILtJ. We also showed a lower proportion of
private SNPs in the TH strain than discovered in FVB/
NJ [30]. The proportion of private indels we observed in
TH was higher than in these studies. Although the ori-
gins of the Theiler Original mouse are unknown, the
generally higher proportion of private variants in TH
(compared to most laboratory strains) is consistent with
the possibility that TH has a unique ancestor. We also
note that our sequencing coverage of 64.8X was higher
than in these other studies, increasing our general power
to detect variants.
Classification of variants
We provided a comprehensive catalog of variants of the
TH mouse, relative to the B6 mouse, classified according
to the effect of the variant on protein sequence. These
effects were predicted by comparing the location of the
variant on the reference genome to known genomic an-
notations provided by the Ensembl gene database [52].
While it is relatively straightforward to automate the
classification of a large number of variants via genomic
annotations on a coarse scale, providing detailed inter-
pretations of the effect of some mutations requires
greater inspection of the context of the mutation that
cannot be readily automated and performed on a
genome-wide scale. For example, the effect of intronic
mutations is not well characterized or understood at
present. Our aims in this study include both providing a
general overview of the landscape of the TH mouse gen-
ome relative to the reference genome, and also providing
sufficient detail of the nature of the 5.3 million variants
discovered. To this end, we used an automated process
to classify variants into a large number of precisely
defined categories, and then subsequently reduced the
number of these categories, subjectively categorizing
them into a smaller set of representative terms. The first
categorization provides a fine-grained resource for
searching for individual variants that may have pheno-
typic consequences, and the second provides a general
overview of the landscape of the TH genome.
The Sequence Ontology (SO) [37] provides a con-
trolled vocabulary for describing features and annota-
tions associated with a biological sequence, including
mutations at the sequence level, along with a formalized
description of the relationships between these terms.
The Variant Effect Predictor (VEP) [36] is a tool that
predicts the effect of genomic variants by analyzing the
variant in the context of annotations on the reference
genomic sequence. For each variant and each known
transcript containing that variant, VEP outputs a subset
of SO terms associated with that variant. In many cases,
this results in multiple SO terms being associated with a
single variant in the context of a single transcript. For
example, we found an A to G single nucleotide poly-
morphism (SNP) at genomic location 126,585,377 on
chromosome 7. This SNP occurs in the second nucleo-
tide of the first codon of the second exon of the apolipo-
protein B receptor gene, Apobr, mutating the GAC
codon to GGC. Since this mutation results in a change
in amino acid from aspartic acid to glycine, the SNP is
annotated with the SO term “missense_variant”. Since
this variant also occurs within three bases of a splice site,
it is also annotated with the SO term “splice_region_var-
iant”. In order to provide a complete, unbiased
characterization of the types of variants discovered, we
list all unique combinations of SO terms for a single
variant and the number of times those combinations
occur (Additional file 2: Table S2 and Additional file 3:
Table S3).
In order to provide a concise overview of the relative
proportions of occurrences of the major types of vari-
ants, for each unique combination of SO terms we
selected a “representative” SO term (Additional file 2:
Table S2 and Additional file 3: Table S3, second col-
umn). These overviews are presented in Figs. 2 and 3.
Due to the presence of multiple transcripts for some
genes, and due to the presence of overlapping genes,
some individual variants are present in multiple tran-
scripts. In this case, VEP outputs a potentially different
combination of SO terms for each of the transcripts in
which the variant occurs. When there are multiple,
distinct, combinations for a given variant due to its pres-
ence in multiple transcripts, these variants are catego-
rized in Additional file 2: Table S2 and Additional file 3:
Table S3 as “multiple classification sets”. In order to
uniquely classify such variants in the overview (Figs. 2
and 3), we picked a representative SO term for each set
of SO terms using the strategy shown in Additional file
2: Table S2 and Additional file 3: Table S3, and then
chose the most pathogenic out of these representative
SO terms using the priority described in the methods.
Filtering variants by the human GWAS catalog
We employed a translational methodology to identify
and prioritize candidate genes for complex disorders for
which TH is a model. We examined all the TH variants
for potential link to relevant human disease using the
EBI GWAS catalog [39] and generated enriched candi-
date gene lists for obesity, diabetes and metabolic
syndrome. We reviewed biological function for selected
genes and identify genes we could connect to obesity
and/or diabetes. GLIS3 is a transcription factor that
plays an important role in pancreatic development and
insulin gene expression in beta cells [53]. SORBS1 is
involved in insulin stimulated glucose transport in adi-
pocytes [54]. IGF2BP2 is a RNA binding protein, partici-
pating in posttranscriptional RNA processing, i.e., RNA
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splicing, stabilization, transport, and translation [55]. In-
activation of the Igf2bp2 gene caused a resistance to
diet-induced obesity in mice [56]. Semaphorin 5A
(Sema5A) is an axon regulator molecule and plays a role
during neuronal and vascular development [57]. Collect-
ively, our convergent approaches systematically inte-
grate whole genome sequencing data and genetic
information from GWAS-derived findings and provide
an opportunity to discover candidate genes for further
functional validation.
Missense polymorphism of R46S in CIDEC between B6
and TH mice
Among the genes with SNPs that were identified as dele-
terious by both SIFT and PROVEAN (Additional file 5:
Table S5), were orthologous to Mendelian lipodystrophy
genes, and were contained within the tabw2 interval, we
identified Cidec, which is an important regulator of
energy homeostasis directly involved in promoting the
accumulation of triglyceride into intracellular lipid drop-
lets [50]. Lipid droplets are spherical organelles found in
many types of eukaryotic cells, including adipocytes, and
are composed of a core of neutral lipids, such as sterol
esters or triglycerides, surrounded by a monolayer of
phospholipids, free cholesterol, and multiple specific
proteins including CIDEC [50]. In adipocytes, cellular
energy is stored as triglycerides in lipid droplets, and in
conditions of fatty acid excess, lipid droplets rapidly
increase their volumes [58]. The capacity of CIDEC in
accumulating triglycerides into intracellular lipid drop-
lets was demonstrated by transfection experiments using
multiple cell types including C pre-adipocytes, 293T
cells, and COS cells [42–44]. For example, transfection
of full-length murine Cidec into COS-7 cells increased
total cellular triglycerides by 50 % [44]. We found that
the TH allele of CIDEC S46 variant allowed for more
lipid accumulation than the B6 allele of CIDEC R46 vari-
ant in COS-1 cells. Further functional validation of this
missense polymorphism in vivo may provide an oppor-
tunity to understand the role of Cidec in the context of
obesity.
Conclusions
We have sequenced the whole genome of obese type 2
diabetic TH mice by next-generation sequencing and
generated a complete catalog of variants classified by
location relative to genes and predicted consequences
for protein products. We filtered the list of variants to
the tabw2 obesity QTL and identified a missense poly-
morphism in Cidec whose protein function we charac-
terized. Furthermore, by comparing the variant catalog
to the human GWAS catalog and to known human
Mendelian obesity genes, we were able to identify a list
of susceptibility candidate genes that could be used to
dissect the components of polygenic diseases such as
obesity and type 2 diabetes.
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